<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>27(4)</volume><submitter>Wang JT</submitter><pubmed_abstract>&lt;h4>Aims&lt;/h4>Type 2 diabetes mellitus (T2DM) can lead to brain dysfunction and a series of neurological complications. Previous research demonstrated that a novel palmitic acid (5-PAHSA) exerts effect on glucose tolerance and chronic inflammation. Autophagy was important in diabetic-related neurodegeneration. The aim of the present study was to investigate whether 5-PAHSA has specific therapeutic effects on neurological dysfunction in diabetics, particularly with regard to autophagy.&lt;h4>Methods&lt;/h4>5-PAHSA was successfully synthesized according to a previously described protocol. We then carried out a series of in vitro and in vivo experiments using PC12 cells under diabetic conditions, and DB/DB mice, respectively. PC12 cells were treated with 5-PAHSA for 24 h, while mice were administere</pubmed_abstract><journal>CNS neuroscience &amp; therapeutics</journal><pagination>484-496</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7941174</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A novel palmitic acid hydroxy stearic acid (5-PAHSA) plays a neuroprotective role by inhibiting phosphorylation of the m-TOR-ULK1 pathway and regulating autophagy.</pubmed_title><pmcid>PMC7941174</pmcid><pubmed_authors>Xue JZ</pubmed_authors><pubmed_authors>Xu XD</pubmed_authors><pubmed_authors>Xue WJ</pubmed_authors><pubmed_authors>He CF</pubmed_authors><pubmed_authors>Wang JT</pubmed_authors><pubmed_authors>Wen XH</pubmed_authors><pubmed_authors>Tao YH</pubmed_authors><pubmed_authors>Zhang Q</pubmed_authors><pubmed_authors>Wang YM</pubmed_authors><pubmed_authors>Guo QL</pubmed_authors><pubmed_authors>Zhou HG</pubmed_authors><pubmed_authors>Guo JC</pubmed_authors><pubmed_authors>Yu ZY</pubmed_authors><pubmed_authors>Liu YC</pubmed_authors></additional><is_claimable>false</is_claimable><name>A novel palmitic acid hydroxy stearic acid (5-PAHSA) plays a neuroprotective role by inhibiting phosphorylation of the m-TOR-ULK1 pathway and regulating autophagy.</name><description>&lt;h4>Aims&lt;/h4>Type 2 diabetes mellitus (T2DM) can lead to brain dysfunction and a series of neurological complications. Previous research demonstrated that a novel palmitic acid (5-PAHSA) exerts effect on glucose tolerance and chronic inflammation. Autophagy was important in diabetic-related neurodegeneration. The aim of the present study was to investigate whether 5-PAHSA has specific therapeutic effects on neurological dysfunction in diabetics, particularly with regard to autophagy.&lt;h4>Methods&lt;/h4>5-PAHSA was successfully synthesized according to a previously described protocol. We then carried out a series of in vitro and in vivo experiments using PC12 cells under diabetic conditions, and DB/DB mice, respectively. PC12 cells were treated with 5-PAHSA for 24 h, while mice were administere</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Apr</publication><modification>2025-04-22T10:48:53.108Z</modification><creation>2025-04-05T23:39:46.676Z</creation></dates><accession>S-EPMC7941174</accession><cross_references><pubmed>33459523</pubmed><doi>10.1111/cns.13573</doi></cross_references></HashMap>